A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension (LOTUSDI)

Allergan

Status and phase: Completed; Phase 4

Conditions: Ocular Hypertension; Glaucoma, Open-Angle

Treatments: Drug: 0.03% Bimatoprost

Study type: Interventional

Funder types: Industry

Identifiers

NCT02020512

CN-BIM-1102

Details and patient eligibility

About

This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.

Enrollment: 87 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of open-angle glaucoma or ocular hypertension
• No use of Lumigan® in the past 3 months

Exclusion criteria

• Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

87 participants in 1 patient group

0.03% Bimatoprost

Experimental group

Description:

0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.

Treatment:

Drug: 0.03% Bimatoprost